Evaluation of a fully automated assay for the measurement of plasma pTau217 and a composite score integrating the ratio Aβ1-42/1-40 as biomarkers of Alzheimer’s disease
Authors:
- Barbara MorgadoBMBarbara Morgado
- Hans-Wolfgang KlafkiHKHans-Wolfgang Klafki
- Chris BauerCBChris Bauer
- Annik SteiertASAnnik Steiert
- Katharina WaniekKWKatharina Waniek
- Ingolf LachmannILIngolf Lachmann
- Dirk OsterlohDODirk Osterloh
- Hermann EsselmannHEHermann Esselmann
- Niels HansenNiels Hansen
- Johannes SchuchhardtJSJohannes Schuchhardt
- Jens WiltfangJWJens Wiltfang
Open Access
- 27 September 2025
- journal article
- research article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (5) , 1-14
Abstract
Background: Plasma phosphorylated Tau217 (pTau217) represents a sensitive blood-based biomarker for Alzheimer’s disease (AD). This study investigated the performance of plasma pTau217 alone and as a composite score (Aβ1-40/Aβ1-42*pTau217) for detecting low Aβ1-42/1-40 in cerebrospinal fluid (CSF) as a surrogate marker of brain β-amyloid pathological changes. Methods: We analysed plasma samples from 82 pre-selected participants who were dichotomized according to their CSF Aβ42/40 ratio after data-driven cutoff determination by Gaussian mixture modelling. The study cohort included patients in very early disease stages with mild cognitive impairment (MCI) due to AD and mild dementia due to AD in the Aβ-positive group and MCI due to other causes and mild dementia due to other causes in the Aβ-negative group. Concentrations of plasma pTau181 and pTau217 were determined on the fully automated LUMIPULSE platform. Additionally, plasma Aβ1-42/1-40 and pTau217 were assessed after consecutive Aβ- and Tau-immunoprecipitations (IPs). Corrections for age and sex effects in primary variables were done using a multivariate linear model on a logarithmic scale. Results are reported using both adjusted and unadjusted values. Results: After adjustment for age and sex, median plasma pTau217 was increased by 203% in participants with low CSF Aβ1-42/1-40 (i.e. Aβ-positive), while pTau181 was increased by only 61%. PTau217 showed a larger area under the receiver operating characteristics curve (AUC) of 0.88 in identifying Aβ-positive individuals compared to plasma pTau181 (AUC: 0.78). Plasma Aβ1-42/1-40 ratio in Aβ-IP eluates (adjusted for age and sex) was decreased by only 10%, and the standardized effect size (Cohen´s d) was smaller than that of pTau217. Tau-IP did not improve the performance of the pTau217 assay (p = 0.568, DeLong test). However, the Aβ1-40/Aβ1-42*pTau217 ratio following immunoprecipitations appeared to outperform the single blood biomarkers. Conclusion: PTau217 as measured with the fully automated Lumipulse G pTau217 Plasma < RUO > assay demonstrated high accuracy for detecting low CSF Aβ1-42/1-40 and appears to represent a particularly attractive biomarker for future implementation in clinical practice. Furthermore, the composite score Aβ1-40/Aβ1-42*pTau217 showed promise for enhancing the blood-based early and differential diagnosis of AD.Keywords
Funding Information
- Herzzentrum Göttingen
This publication has 49 references indexed in Scilit:
- Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samplesAlzheimer's & Dementia, 2023
- Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma BiomarkersJAMA Neurology, 2023
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJAMA Neurology, 2023
- Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centersAlzheimer's & Dementia, 2022
- Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tauAlzheimer's & Dementia, 2021
- Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer DiseaseJAMA Neurology, 2021
- Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosisAlzheimer's & Dementia, 2020
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on LumipulseAnnals of Clinical and Translational Neurology, 2019
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010